Next-Generation Sequencing Assay for biomarker analysis

The assay is a multi-biomarker next-generation sequencing (NGS) assay that enables detection of thousands of variants relevant to solid tumors. This assay allows concurrent analysis of DNA & RNA to simultaneously detect multiple types of variants.

Intelligent NGS Assay

The biomarkers included in our assay were selected by the oncology informatics team based on proprietary databases, peer-reviewed literature, and competitive industry data, and confirmed with industry-leading pharmaceutical partners.

Prognosis of disease
Prediction of Potential Metastasis
Targeted therapy
Relevant, on-going clinical trial information

A solid tumor is an abnormal mass of tissue that is free from cysts or liquid. There are three classes of malignant solid tumors: sarcomas, carcinomas and lymphomas. Old school treatments depend only on the cancer’s location, the stage, and the patient’s health. New targeted therapies are specific for the individual patient’s mutational profile, which requires advanced sequencing technology. Ayass BioScience, LLC has the capability to provide this much needed information for precision therapies.

Results in Less Than 48 Hours!

Bladder cancer
Breast cancer
Colorectal cancer
Endometrial cancer
Esophageal cancer
Gastric cancer
GIST
Glioblastoma
Head and neck cancer kidney cancer
Liver cancer
Lung cancer
Melanoma
Mesotelioma
NSCLC
Osteosarcoma
Ovarian cancer
Pancreatic cancer
Prostate cancer
Skin basal cell carcinoma
SLCLC
Soft tissue sarcome
Testicular cancer
Thyroid cancer
Unspecified cancer
Unspecified solid tumor

AKT1, AKT2, AKT3, ALK, AR, ARAF, AXL, BRAF, BTK, CBL, CCND1, CDK4, CDK6, CHEK2, CSF1R, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ERCC2, ESR1, EZH2, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FOXL2, GATA2, GNA11, GNAQ, GNAS, H3F3A, HIST1H3B, HNF1A, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KDR, KIT, KNSTRN, KRAS, MAGOH, MAP2K1, MAP2K2, MAP2K4, MAPK1, MAX, MDM4, MED12, MET, MTOR, MYC, MYCN, MYD88, NFE2L2, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PPP2R1A, PTPN11, RAC1, RAF1, RET, RHEB, RHOA, ROS1, SF3B1, SMAD4, SMO, SPOP, SRC, STAT3, TERT, TOP1, U2AF1, XPO1

ARID1A, ATM, ATR, ATRX, BAP1, BRCA1, BRCA2, CDK12, CDKN1B, CDKN2A, CDKN2B, CHEK1, CREBBP, FANCA, FANCD2, FANCI, FBXW7, MLH1, MRE11A, MSH2, MSH6, NBN, NF1, NF2, NOTCH1, NOTCH2, NOTCH3, PALB2, PIK3R1, PMS2, POLE, PTCH1, PTEN, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RB1, RNF43, SETD2, SLX4, SMARCA4, SMARCB1, STK11, TP53, TSC1, TSC2

AKT1, AKT2, AKT3, ALK, AR, AXL, BRAF, CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, EGFR, ERBB2, ESR1, FGF19, FGF3, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, IGF1R, KIT, KRAS, MDM2, MDM4, MET, MYC, MYCL, MYCN, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PPARG, RICTOR, TERT

AKT2, ALK, AR, AXL, BRAF, BRCA1, BRCA2, CDKN2A, EGFR, ERBB2, ERBB4, ERG, ESR1, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, FGR, FLT3, JAK2, KRAS, MDM4, MET, MYB, MYBL1, NF1, NOTCH1, NOTCH4, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PDGFRB, PIK3CA, PPARG, PRKACA, PRKACB, PTEN, RAD51B, RAF1, RB1, RELA, RET, ROS1, RSPO2, RSPO3, TERT

OUR REPORT CONTAINS:

Prognostic Information

Incidence • Mortality • Survival • Stage • Prevalence • Lifetime Risk

To estimate prognosis we are using statistics that researchers have collected over many years about people with the same type of cancer. Available statistics may include incidence, mortality, survival, stage, prevalence, and lifetime risk.

Prediction of Potential Metastasis

Metastasis describes the capacity of tumor cells to infiltrate lymphatics and blood vessels and reach and invade other normal tissues. Using tumor sequencing data, Ayass BioScience, LLC has developed a machine learning algorithm to determine the metastasis potential of a tumor sample as well as identify likely metastatic locations based on key variants. The results are summarized as part of the report provided to the clinician to assist them in making informed decisions for their patient.

Targeted therapies

DNA Repair and Cell Cycle Pathway Genes

Targeted therapy is a type of cancer treatment that targets proteins that control how cancer cells grow, divide, and spread.
It is the foundation of precision medicine. Knowing DNA changes and proteins that drive cancer, physicians will able to design treatments that target these proteins.

Identification of Relevant on-going clinical trials

Clinical trials of targeted therapy and other cancer treatments take place in cities and towns across the United States and throughout the world. They take place in doctors’ offices, cancer centers, medical centers, community hospitals and clinics, and veteran and military hospitals. We will help to identify relevant clinical trials.

Our clear and concise reports support clinicians and pathologists in the making of informed treatment decisions. The reports summarize relevant biomarker findings and link them with information from public sources.

All tests are performed in Ayass BioScience, LLC. Ayass BioScience, LLC (DBA Ayass Laboratory, LLC) is a CLIA certified laboratory. If you have any questions about COVID-19 Testing, Genetic Testing, Clinical Testing, Pharmacogenetic Testing or Research at Ayass BioScience, LLC, please call today at 972-668-6005 or fill out our contact form on the bottom of this page. We will answer any question you might have.